Business Description
Genprex Inc
NAICS : 325412
SIC : 2834
ISIN : US3724462037
Total Employee Number:
13Description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.83 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 74.4 | |||||
3-Year EPS without NRI Growth Rate | 74 | |||||
3-Year FCF Growth Rate | 71.9 | |||||
3-Year Book Growth Rate | -86.2 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.52 | |||||
9-Day RSI | 48.62 | |||||
14-Day RSI | 43.97 | |||||
3-1 Month Momentum % | -48.78 | |||||
6-1 Month Momentum % | -66.45 | |||||
12-1 Month Momentum % | -94.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.61 | |||||
Quick Ratio | 5.61 | |||||
Cash Ratio | 5.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -415.7 | |||||
Shareholder Yield % | -444.77 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -270.48 | |||||
ROA % | -190.65 | |||||
ROIC % | -536.31 | |||||
3-Year ROIIC % | -302.91 | |||||
ROCE % | -256.76 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.3 | |||||
Price-to-Tangible-Book | 0.3 | |||||
EV-to-EBIT | 0.74 | |||||
EV-to-EBITDA | 0.74 | |||||
EV-to-FCF | 0.83 | |||||
| Price-to-Net-Current-Asset-Value | 0.33 | |||||
| Price-to-Net-Cash | 0.35 | |||||
Earnings Yield (Greenblatt) % | 135.14 | |||||
FCF Yield % | -231.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GNPX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genprex Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -15.292 | ||
| Beta | -2.1005 | ||
| 3-Year Sharpe Ratio | -0.25 | ||
| 3-Year Sortino Ratio | -0.76 | ||
| Volatility % | 97.12 | ||
| 14-Day RSI | 43.97 | ||
| 14-Day ATR ($) | 0.065616 | ||
| 20-Day SMA ($) | 0.55114 | ||
| 12-1 Month Momentum % | -94.99 | ||
| 52-Week Range ($) | 0.4229 - 55 | ||
| Shares Outstanding (Mil) | 10.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genprex Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genprex Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 127 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 36 days | ||
| General meeting for 2026 | 2026-06-18 09:30 | 0.48 (+14.28%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 0.83 (-2.35%) | ||
| Annual report for 2025 | 2026-03-30 | 1.82 (-3.70%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 4.14 (-10.00%) | ||
| 0.02:1 Stock Split | 2025-10-21 | 14.00 (-18.44%) | ||
| General meeting for 2025 | 2025-08-15 09:30 | 10.80 (-2.26%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 11.26 (-1.01%) | ||
| First quarter earnings results for 2025 | 2025-05-12 | 14.27 (+4.51%) |
Show
Entries
Genprex Inc Frequently Asked Questions
What is Genprex Inc(GNPX)'s stock price today?
The current price of GNPX is $0.56. The 52 week high of GNPX is $55.00 and 52 week low is $0.42.
When is next earnings date of Genprex Inc(GNPX)?
The next earnings date of Genprex Inc(GNPX) is 2026-08-14 Est..
Does Genprex Inc(GNPX) pay dividends? If so, how much?
Genprex Inc(GNPX) does not pay dividend.
Guru Commentaries on NAS:GNPX
No articles.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers